Neuro Vigor is an Indiana startup from Purdue University, built on 15 years of research from neuroscientist Riyi Shi. They have found a new use for the generic drug hydralazine, which is commonly used in cases of hyptertension. Shi is working with the drug as treatment for neurodegenerative diseases such as neuropathies, Parkinson’s, and multiple sclerosis. Hydralazine can bind to and lower acrolein levels in the body, which stops acrolein from attacking and degenerating nerve cells. The company is excited to apply their finding to cases of multiple sclerosis, where there already exists promising research. Neuro Vigor is currently looking to raise funds so they can move into Phase 2 clinical trials, and present the drug to the FDA.


For more information, please see MedCity News.